Risk of Albuminuria Higher With Dasatinib Than With Other TKIs
Patients with CML have a higher risk of albuminuria if they receive dasatinib rather than other TKIs, a study suggests.
Diagnosis & Disease Information
FDA Fast Tracks TMPRSS6 Inhibitor for Polycythemia Vera
The FDA has granted fast track designation to MWTX-003 (DISC-3405) for the treatment of patients with polycythemia vera.
Cisplatin Shortage Nearly Resolved; Supplies of Carboplatin, Methotrexate Increasing
The US supply of cisplatin is nearly restored, and shortages of carboplatin and methotrexate have been alleviated, the government says.
Ranitidine Does Not Increase the Risk of Cancer, Study Suggests
A meta-analysis suggests that ranitidine does not pose an increased risk of cancer when compared to other histamine-2 receptor antagonists.
Final Results of DREAMM-2 Show Durable Responses With Belantamab Mafodotin
Final results from the DREAMM-2 trial suggest that belantamab mafodotin produces durable responses in patients with relapsed/refractory multiple myeloma.
Ojjaara Approved for Intermediate or High-Risk Myelofibrosis With Anemia
The FDA has approved Ojjaara (momelotinib) for the treatment of intermediate or high-risk myelofibrosis in adults with anemia.
Dose-Intensive Chemoimmunotherapy “Preferred” for Untreated PMBCL
Dose-intensive chemoimmunotherapy may be more effective than standard chemoimmunotherapy in PMBCL, a meta-analysis suggests.
Vitamin C, D Supplementation During Chemo May Reduce Complications in AML
Taking vitamin C and D during chemotherapy may improve some outcomes for patients with AML, a new study suggests.
Aphexda Approved for Stem Cell Mobilization in Multiple Myeloma
Aphexda (motixafortide) is expected to be available later this month.
Melflufen Demonstrates Efficacy in LIGHTHOUSE Trial; Drug’s Future Still Unclear
Melflufen plus daratumumab and dexamethasone produced better outcomes than daratumumab alone in a phase 3 trial of patients with relapsed/refractory multiple myeloma.
- Loading...
Loading...
Next post in Multiple Myeloma
Loading... 
Loading...